ReviewDrug design, development and therapy2026
Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major driver of Cardiovascular-Kidney-Metabolic (CKM) syndrome and contributes to the development of atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, chronic kidney disease, and type 2 diabetes. Historically, oral obesity pharmacotherapy was evaluated primarily according to weight loss efficacy. However, the emergence of the CKM framework has shifted therapeutic priorities toward modifying obesity related complications and improving long term clinical outcomes. This review summarizes currently approved oral obesity medications, including first generation agents (orlistat, phentermine/topiramate, and naltrexone/bupropion) and second generation incretin-based therapies (oral semaglutide and orforglipron), within the context of CKM syndrome. First generation agents provide modest-to-moderate weight loss and variable metabolic benefits, but evidence supporting cardiovascular or kidney outcome improvement remains limited and largely observational. In contrast, oral incretin-based therapies demonstrate broader effects across the CKM spectrum, including substantial weight reduction, improved glycemic control, favorable effects on blood pressure and triglycerides, and emerging kidney benefits. Among currently available oral agents, oral semaglutide has the strongest evidence, with the SOUL trial demonstrating a reduction in major adverse cardiovascular events in high-risk individuals with type 2 diabetes. Signals suggesting benefits in heart failure and atrial fibrillation are encouraging but remain exploratory. Orforglipron represents the first non-peptide oral glucagon-like peptide-1 receptor agonist and offers simplified administration with promising metabolic efficacy; however, cardiovascular, kidney, heart failure, and arrhythmia outcome data are still awaited. Collectively, the role of oral obesity pharmacotherapy is evolving from weight management alone toward comprehensive CKM care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.